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Abstract: IL-6 is a cytokine that is involved in various physiological and pathological conditions, and 
approaches using gain-of-function transgenic animals have contributed in elucidating IL-6 function. 
However, studies of the multiple functions of IL-6 in vivo are very time consuming because they 
require the generation of transgenic mice that harbor the gene encoding IL-6 under the control of 
specific promoters to mimic different pathologies. Here, we report the establishment of a conditional 
human IL-6 transgenic mouse, LGL-IL6, which conditionally expresses human IL-6 by taking advantage 
of the well-characterized Cre recombinase drivers.
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Introduction
IL-6 is among the major cytokines that mediate inflam-
mation. IL-6 plays important roles in acute inflammation 
and in various physiological and pathological conditions, 
such as aging, obesity, diabetes, osteoporosis, rheuma-
toid arthritis, osteoarthritis, sepsis, cognitive function, 
and fibrosis [1, 2, 6–8, 10, 20]. The IL-6 signal is trans-
duced by its receptors IL-6R and gp130 and modulates 
downstream gene expression, such as Socs3, by phos-
phorylating sTaT3. of clinical importance, the interven-
tion of the iL-6 signaling has been already applied to 
treatments for rheumatoid arthritis and Castleman’s 
disease [9, 13].
Transgenic approaches for studying the in vivo func-
tion of iL-6 have been conducted during the last three 
decades. The earliest reports found that transgenic ex-
pression driven by the immunoglobulin heavy-chain 
enhancer or the major histocompatibility complex class-
i promoter induces igg1 plasmacytosis or plasmacyto-
mas, respectively [17, 18]. The overexpression of IL-6 
in skin by the keratin 14 promoter induces the thickening 
of the stratum corneum but not inflammation of the skin 
[19]. Moreover, multiple pathogenic alterations occur in 
mice that express IL-6 through glial fibrillary acidic 
protein or neuron-specific enolase gene promoter to tar-
get glial cells or neurons, respectively [3, 5]. Humanized 
iL-6/iL-6 receptor system in mice has been more re-
cently developed via the transgenic approach to demon-
strate IL-6 pathology [21].
However, the establishment of a transgenic line with 
a defined promoter activity is labor intensive. Constitu-
tive overexpression of a transgene typically occurs when 
the promoter is active, for example, during embryogen-
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esis and/or perinatally. Moreover, because iL-6 is often 
pathogenic, the overexpression of iL-6 during embryo-
genesis may be lethal and, even they survived, it may 
result in selecting founders that keep the expression 
levels of the transgene as low as avoiding the lethality 
and maintaining the fertility for propagation. It is difficult 
to generate individual gain-of-function transgenic lines 
to study the multiple in vivo functions of iL-6 for each 
pathology. Here, we report the establishment of a trans-
genic line that conditionally expressed human iL-6. it 
enables to drive spatiotemporal expression of human 
iL-6 by appropriate Cre-dependent recombination.
Materials and Methods
Materials
The mouse hybridoma cell line 7-TD-1 was obtained 
from RIKEN Cell Bank (resource number RCB1190). 
recombinant human iL-6 and tamoxifen were purchased 
from Wako (Osaka, Japan) and Sigma-Aldrich (St. 
Louis, Mo, usa), respectively.
Construction of IL6-T2A-mCherry
To monitor the transgene expression by fluorescence 
in vivo, the human iL-6 coding sequence was fused to 
T2A-mCherry from pUbC-rLoxP-mChe [16]. The 
mCherry sequence was modified adding a signal sequence 
from the mouse proacrosin at the N-terminus for extracel-
lular sorting and a consensus sequence for attaching a 
glycosylphosphatidylinositol (gPi)-anchor at the C-ter-
minus to detect the fluorescence associated with the 
plasma membrane [16]. Because the self-cleaving T2A 
peptide was digested at the C-terminal site of the peptide, 
the resulting iL-6 peptide was extended with a 21-amino 
acid stretch (gragegrgsLLTCgdVeeNPg) by the 
cleavage. dNa fragments were fused using PCr and the 
InFusion HD Kit (Takara Bio, Shiga, Japan) combined 
with peF4-mycHisa (invitrogen, Carlsbad, Ca, usa) 
to construct the expression plasmid peF4-hiL6-T2a-
mCherry. The sequence was confirmed by sequencing.
Transfection and fluorescence microscopy
HEK293T cells do not express detectable endogenous 
IL-6 or IL-6 receptor. HEK293T cells were transfected 
without (mock) or with peF4-hiL6-T2a-mCherry using 
FugeNe Hd Transfection reagent (Promega, Madison, 
wi, usa), according to manufacturer’s protocol. Cells 
and cell culture supernatants were assayed 48 h after 
transfection. To estimate the protein level of the human 
iL-6, eLisa was performed as described bellow. To 
detect the expression of mCherry, the transfected cells 
were photographed using a BIOREVO fluorescence mi-
croscope (Keyence, Osaka, Japan).
Generation of LGL-IL6 mice
The CAG promoter [14] was used to drive the ubiq-
uitous expression of the transgene. EGFP and SV40 
polyadenylation signal sequences were inserted between 
the two loxP sites to block transcription through the iL6-
T2a-mCherry sequence in the absence of Cre activity. 
dNa fragments were generated using PCr and com-
bined using the inFusion kit that are described above. 
Nucleotide sequence analysis was conducted to confirm 
the structure of the construct. The vector sequence will 
be provided on request.
a 5.4 kbp Dra iii-Xho i fragment was isolated to re-
move the vector region and the purified DNA fragment 
was injected into fertilized pronuclear-stage eggs of 
C57BL/6NCrSlc (SLC, Shizuoka, Japan), and then healthy 
eggs were transplanted into recipients. genomic PCr was 
performed to identify founders, and PCr was used to 
determine the genotypes of mice harboring the transgene 





rosa-CreerT2 mice (B6.129-Gt (ROSA) 26Sortm1 (cre/
ERT2) Tyj/J, Stock 008463) were obtained from the Jackson 
Laboratory [23]. Mice were mated to produce offspring 
that carried LgL-iL6 and rosa-CreerT2 (Cre/tg), geno-
typed, and treated with tamoxifen that was dissolved in 
canola oil (20 mg/ml). Tamoxifen (100 mg/kg) was in-
traperitoneally injected into 4-week-old mice on days 0 
and 7 and were sacrificed on day 10. Littermates of the 
Cre/tg mice harboring either the LgL-iL-6 or rosaCre-
erT2 transgene served as controls. Mice were housed in 
specific pathogen-free condition in the animal facility of 
National Center for geriatrics and gerontology (NCgg). 
all animal experiments were performed according to the 
protocols approved by the ethics Committee for animal 
experimentation of NCgg.
Human IL-6 ELISA
an iL-6 eLisa kit (Human) was purchased from 
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diaclone (besançon, France). Conditioned media pre-
pared from supernatants of cultures of HEK293T cells 
were stored at −80°C until assay. The frozen medium 
was thawed and diluted 1:100,000 in PBS. The concen-
trations of human iL-6 in the diluted samples were mea-
sured using the eLisa kit, according to the manufac-
turer’s protocol. Mouse serum samples were diluted 
1:5,000 in PBS for analysis. Each sample was tested at 
least in triplicate, and the values were obtained from 
mice of each genotype (n=4 per group).
IL-6 bioassay
To measure the specific activity of human IL-6 that was 
expressed by hiL6-T2a-mCherry, we performed a bioas-
say using the IL-6 dependent 7-TD-1 cell line [22]. Se-
rial dilutions of the conditioned medium from mock, 
peF4-hiL6-T2a-mCherry-transfectants, or recombinant 
hIL-6 were added to flat-bottom microwells. The super-
natant from mock-transfected cells served as the negative 
control. 7-TD-1 cells (5 × 103) were added to each well 
and incubated for 72 h at 37°C. Cell proliferation was 
determined using a Cell Counting Kit-8 (Dojindo Labo-
ratories, Kumamoto, Japan), and specific activity was 
determined by the relative values to the protein content. 
One unit was calculated as 106/ED50 of the culture media 
or commercially available recombinant iL-6, in which a 
half-maximal proliferation of 7-TD-1 cells was adopted.
Confocal imaging
Mouse kidney sections were visualized using an LSM 
5 eXCiTer confocal laser microscope (CarlZeiss, 
oberkochen, germany). dual-color images were cap-
tured in a sequential manner. all images were obtained 
using a ×63 oil-immersion objective. Scanning was per-
formed with a pinhole size of 1.0 airy unit and seventeen 
times line averaging. The images were stored in a 574 × 
574-pixel, 12-bit TIFF file format.
SDS-PAGE and immunoblot analyses
Mouse serum proteins (0.3-µl serum equivalent) were 
subjected to SDS-PAGE under reducing conditions [11] 
and detected using Cbb. For immunoblotting, serum 
(0.2-µl serum equivalent) or tissue proteins (10 µg) that 
were separated using sds-Page were electrophoreti-
cally transferred to a polyvinylidene difluoride mem-
brane (Bio-Rad, Hercules, CA, USA) that was first im-
mersed in the startingblock blocking buffer in Tbs 
(Thermo Fisher Scientific, Waltham, MA, USA). Blots 
were probed with the following antibodies: psTaT3 mab 
(diluted 1:100,000; Abcam, Cambridge, UK), Stat3 pAb 
(diluted 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA), β-actin DirecT (diluted 1:30,000; MBL, 
Aichi, Japan), or mouse IgG (diluted 1:20,000; GE 
Healthcare, Chicago, iL, usa) using immunostar Ld 
or Zeta (Wako). Blots were imaged using the LAS 4000 
Imaging System (Fujifilm, Tokyo, Japan).
Real-time PCR
Total rNa was isolated using an mirNeasy kit (Qia-
geN, Hilden, germany), according to the manufacturer’s 
instructions. Total rNa was treated with rNase-free 
dNase (QiageN) to eliminate possible contamination 
with genomic DNA. The template was synthesized using 
Superscript VILO (Thermo Fisher Scientific), and real-
time PCr was performed using sYbr Premix Ex Taq ii 
reagents (TOYOBO, Osaka, Japan) and a CFX96 Real-
Time PCr detection system (bio-rad). For the tissue 
distribution of the transgene expression, the copy 
number of the rNa was calculated using serial dilution 
of the amplicon and arbitrary units were given by the 
copy number of the transgene-specific mrNa per 1 ng 
of rNa. For the expression of the downstream genes 
for iL-6 signaling, the mean values of the expression 
in relative to those The primers (P1 and P2) specific 
for the human IL6 transgene were as follows: P1, 
5′-GTAGACTCGACTAGCTTGGGCTG-3′ and P2, 
5′-TGGGGCGGCTACATCTTTGGAATC-3′. Other 




all data are expressed as mean ± sd. To compare 
mrNa levels expressed by the control vs. Cre/tg mice, 
statistical analysis was performed using a two-tailed 
unpaired student’s t-test (StatFlex 6 software; Artech, 
Osaka, Japan).
Results
In vitro expression of the hIL-6-mCherry construct
To enable monitoring transgene expression by visual-
izing the expressing cells with red fluorescence, human 
IL6 cdNa was fused to mCherry mediated by T2a, an 
autocleavable peptide in the cells (Fig. 1a). To distin-
guish the transgene product from the endogenous iL-6, 
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human iL-6, which can activate mouse iL-6 signaling 
pathway, was used for this study. The mCherry was 
modified by addition of signal peptide and GPI-anchor-
ing sequences at the N-terminal and C-terminal ends, 
respectively, to achieve cell surface expression. To con-
firm the validity of the construct, the IL6-T2A-mCherry 
unit was expressed in HEK293T cells. When pEF4-hIL6-
T2A-mCherry was transfected in HEK293T cells, the 
red fluorescence was detected on the cells but not on 
mock-transfected cells (Fig. 1b). using eLisa, the con-
centration of human iL-6 in the culture medium of the 
transfected cells was 5.6 µg/ml (Fig. 1C) but was unde-
tectable in a medium that was harvested from cultures 
of the mock-transfected cells.
it has been reported that the C-terminal sequence of 
IL-6 was important for its activity [12]. Therefore, it was 
Fig. 1. expression of iL-6-T2a-mCherry. a, structure of the expression unit in peF4-hiL6-T2a-mCherry. b, Fluo-
rescent images of mCherry in HEK293T cells transfected with empty vector (left panel, mock) or pEF4-hIL6-
T2a-mCherry (right panel, mCherry). C, expression of iL-6 proteins in the culture medium of the transfected 
cells. Concentration of IL-6 expressed in the culture medium was measured by ELISA. D, Specific activities 
of IL-6 proteins. By bioassay for IL-6 using a mouse hybridoma cell line, 7-TD-1, the specific activities of 
recombinant human IL-6 were compared (n=3). Control, biologically active recombinant human IL-6 (Wako); 
hiL-6, human iL-6 detected in the culture media of cells transfected with peF4-hiL6-T2a-mCherry.
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crucial to verify the activity of the present human iL-6 
construct containing C-terminal extension of 21 amino 
acid residues that are derived from T2a sequence (Fig. 
1A). The culture medium from the transfected 293T cells 
was subjected to bioassay of IL-6 using 7-TD-1 cells. 
As shown in Fig. 1D, the specific activity of the culture 
medium was comparable with that of a biologically ac-
tive recombinant IL-6 (1.02 ± 0.09 vs. 1.05 ± 0.10 (108 
units/mg)), suggesting that the human iL-6 expressed by 
iL6-T2a-mCherry unit possessed biological activity that 
was sufficient for use as a transgene in vivo.
Generation of transgenic mice that conditionally express 
hIL-6
To achieve Cre-dependent conditional expression, a 
sequence encoding EGFP-polyA with flanking loxP ele-
ments was introduced upstream of the hiL-6-mCherry 
sequence (Fig. 2a). of eight transgenic founders, two 
failed to propagate. Transgene expression, monitored by 
egFP expression, was detected in the progeny of three 
lines. The expression of the transgene declined during 
the propagation in one of the lines, and the other two 
lines designated Li29 and Li56 were obtained as the 
conditional transgenic mice, LGL-IL6. Li29 expressed 
the transgene in all tissues tested, and thus, was sub-
jected to further analysis.
Next, we mated Li29 with a Rosa-CreERT2 mouse to 
generate a progeny with tamoxifen-dependent systemic 
expression of the transgene. Following an intraperito-
neal injection of tamoxifen, transgene expression was 
detected only in mice with the rosa-CreerT2/LgL-iL6 
(Cre/tg) genotype (Fig. 2b), and iL-6 expression was 
detected in all tissues tested. The administration of 
tamoxifen increased the serum IL-6 levels (~92 ng/ml) 
of the Cre/tg mice, whereas those of the control mice 
were undetectable (Fig. 2C), suggesting that the loxP-
egFP-polya-loxP sequence prevented iL-6 expression 
by the transgene. with the same protocol, the massive 
death has been observed in Li56 mice that were com-
pound heterozygotes of Rosa-CreERT2 (not shown).
To validate the system, fluorescent images of the tis-
sues from the mice were analyzed. In Fig. 2D, green 
fluorescent originated by EGFP was observed in LGL-
iL6 and rosa-CreerT2/LgL-iL6 mice, but not in wild-
type mice. The red fluorescence originated by mCherry 
was seen only in rosa-CreerT2/LgL-iL6 mice, but not 
wild-type or LgL-iL6 transgenic mice, suggesting that 
the fluorescence switch by Cre mediated recombination 
has been confirmed in vivo.
Protein patterns in serum
The marked elevation of iL-6 levels in the serum led 
to presume alteration of serum protein profile. As ex-
pected, significant alteration of protein patterns in serum 
was evident (left panel, Fig. 3). The level of serum albu-
min was also significantly decreased in Cre/tg mice, sug-
gesting an abnormality in the physical condition of the 
transgenic mice that was presumably caused by the over-
expression of iL-6. in contrast, igg levels increased in 
Cre/tg mice (right panel, Fig. 3). When Li29 mice were 
injected with tamoxifen once every 2 weeks, some phe-
notypes, including splenomegaly, became pronounced 
(the detailed phenotype will be described elsewhere).
IL-6 signaling in transgenic mice
To verify the action of transgenic iL-6, phosphoryla-
tion levels of sTaT3 were determined in the liver, heart, 
and kidney. as shown in Fig. 4a, the levels of sTaT3 
phosphorylation at Tyr705 in the tissues of Cre/tg mice 
were significantly higher compared with those of control 
mice. Next the expression of Socs3, a common target 
gene of the IL-6 signaling pathway, was analyzed. The 
expression of Socs3 was markedly increased in the tis-
sues of Cre/tg mice comparing to those of control mice, 
suggesting that the tamoxifen-induced transgene expres-
sion evoked the expected responses in the tissues (Fig. 
4b). in addition to the common signaling responses of 
IL-6, gene expression profile in liver was determined. 
several iL-6 responsive genes in liver have been previ-
ously described [4, 15] and used as targets of real-time 
PCr. as shown in Fig. 4C, the changes in expression of 
the genes were consistent with the previous findings, 
well reflecting IL-6 actions in mouse liver [4, 15].
Discussion
Here, we report the systemic and tamoxifen-dependent 
expression of human iL-6 by the progeny of an iL-6 
transgenic mouse line mated with a rosa-CreerT2 trans-
genic mouse. even additional 21 amino acid stretch was 
appended at the C-terminal end, the iL-6 originated from 
the transgene unit was biologically active and well re-
produced the responses previously reported.
The construct was designed to undergo Cre-mediated 
recombination leading to the expression of mCherry 
instead of EGFP [16]. The transgene seemed to present 
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Fig. 2. systemic expression of iL-6 in the LgL-iL6 transgenic mouse line. a, LgL-iL6 transgene (top). in the absence of Cre activity, 
only EGFP protein is expressed. Cre-mediated recombination deletes the floxed EGFP-polyA sequence, allowing the expression 
of iL6-T2a-mCherry. P1 and P2, PCr primers. b, expression of IL6 mrNa in tissues. Mating LgL-iL6 with rosa-CreerT2 
mice generated progeny (rosa-CreerT2/LgL-iL6) that systematically expressed iL-6 after treatment with tamoxifen. arbitrary 
units were calculated as the estimated copy numbers of transgene-specific mRNA per 1 ng of total RNA. Ct, control mice includ-
ing both rosa-CreerT2 and transgenic (LGL-IL6) littermates; Tg, Rosa-CreERT2/LgL-iL6 mice. both mice were treated with 
tamoxifen as described in the Materials and Methods. 1, brain; 2, heart; 3, lung; 4, liver; 5, kidney; 6, spleen; 7, stomach; 8, 
intestine; 9, skeletal muscle; and 10, skin. C, Serum IL-6 levels of Cre/tg mice. ELISA analysis of serum human IL-6 levels of 
control (Ct) and Cre/tg mice (Tg) treated with tamoxifen (n>4). D, Recombination mediated fluorescent protein expression.
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in tandem with multiple copies in the chromosome of 
the line, Li29 (not shown). Theoretically, at least one 
copy of the iL-6-mCherry unit tends to be activated by 
Cre mediated recombination, as evidenced by the gene 
and protein expression, even existed as tandem, although 
variation could be existed. in fact, some egFP expres-
sion was still remained in the tamoxifen-treated Cre/tg 
mice and not uniformly detected in the tissues. although 
the appearance of mCherry signal corresponds to the 
transgene expression in the LgL-iL6 mice, the disap-
pearance of egFP signal was not essential to be evi-
denced for transgene inexpression.
elevation of iL-6 levels in mouse sera was seen with-
in 2 days after a single injection of tamoxifen (not shown). 
In the previous study, serum IgG levels were signifi-
cantly elevated in IL-6 overexpressing mice [17]. The 
difference in the degree of the increase may be explained 
by the differences in the duration of the iL-6 overexpres-
sion and/or the expression levels of iL-6 transgene. al-
though serum iL-6 levels could not be simply compared 
between studies, the serum levels in tamoxifen-treated 
Cre/tg mice reported here were even higher compared 
with those of the transgenic mice with plasmacytosis, 
suggesting that the difference in duration may account 
for the difference between the two phenotypes. However, 
detailed analysis is required to explain the phenotype.
The broad distribution of tissues that expressed the 
transgene harbored by the LgL-iL6 line makes possible 
a wide range of applications of conditional overexpres-
sion of human iL-6 in mice using various Cre trans-
genic lines. Compared with injection, infusion, or both 
of recombinant iL-6, it may be possible to achieve a 
stable and more distinct iL-6-induced pathology if a 
suitable Cre driver is available. The inducibility of the 
expression achieved using the Cre driver is advantageous 
as well. although the limitations in the availability of an 
appropriate Cre driver may be problematic, the number 
of Cre mice with useful distinct genotypes is increasing. 
Therefore, we expect that the LgL-iL6 line will serve 
as a useful tool for studying the function of iL-6 in vivo 
and the pathogenesis of disease mediated by the inap-
propriate expression of iL-6.
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Fig. 4. iL-6 responses in the tissues from Cre/tg mice. a, Phosphorylation of sTaT3 proteins in mouse tissues. Phos-
phorylated STAT3 (pSTAT3 [Y705]), total STAT3 (STAT3), and β-actin proteins were detected by immunoblotting. 
Lanes 1–4, control mice (1–2, Rosa-CreERT2; 3–4, LGL-IL6 mice); lanes 5–8, Cre/tg mice. Tissue sources were as 
indicated. b, real-time PCr analysis of Socs3 expression. Socs3 expression levels are shown as fold-changes of 
Cre/tg mice (Tg) compared with those of control mice (Ct) consist of two rosa-CreerT2 and two LgL-iL6 geno-
types. C, expression of iL-6-responsive genes in the mouse liver. *P<0.05; **P<0.001 (t-test, n=4).
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